Cancer diagnostics
Life often depends on how timely and accurately the diagnosis is made. In addition, accurate diagnosis of oncological diseases is important for making decisions when choosing the most effective treatment tactics in each specific case. To diagnose cancer and determine whether it has spread to other parts of the body, in addition to examination, doctors use data from laboratory and instrumental studies.
At the "Dobrobut" Clinical Oncology Center, everything necessary for complete and accurate diagnosis of oncological diseases is concentrated. We use state-of-the-art equipment from leading manufacturers of medical technology, which is not only informative and effective for diagnosis, but also safe. Moreover, advanced models of diagnostic devices help make the procedure as comfortable as possible.
All diagnostic procedures at the "Dobrobut" Clinical Oncology Center are carried out only with a referral from an oncologist.
Laboratory Diagnostics
A histological conclusion about the pathology is crucial for establishing an accurate diagnosis and selecting the most effective treatment strategy.
Based on the analysis of the obtained biological material, the pathologist helps determine the exact type of cancer. This specialist participates in multidisciplinary councils where decisions about the choice of treatment tactics are made.
Screening laboratory tests for detecting the most common types of cancer include: PAP test (for detecting cervical cancer), PSA test (for detecting prostate cancer), BRCA test (for identifying hereditary predisposition to ovarian and breast cancer), as well as a test for hidden blood in the stool (which helps detect the presence of colorectal cancer and rectal cancer). To determine the nature and type of the tumor, biopsy is used worldwide: the study of tissue samples in laboratory conditions, which are taken from the identified pathological focus.
Service prices:
- PAP-test (screening test of cervical smear)520 uah
- Liquid Cytology CellPrep PAP test940 uah
- Prostate-specific antigen (PSA), general500 uah
- Prostate-specific antigen (PSA), free + general890 uah
- GEN_MyGene BRCA1/2 (NGS, hereditary mutation screening, blood, Illumina)15590 uah
- Fecal immunochemical test (hemoglobin and transferrin)440 uah
- Histological examination after biopsy of bone tumor formation2190 uah
- Histological examination after excisional lymph node biopsy (1 localization)2190 uah
- Histological examination after extirpation of a cervical stump with appendages2280 uah
- Diagnostic IHC, 1st category of difficulty3500 uah
- Diagnostic immunohistochemistryof 2nd category of complexity6420 uah
- Diagnostic IHC, 3rd category of difficulty9810 uah
- HER-2 / neu gene amplification (in situ hybridization, DAKO HER-2 CISH pharmDx set) in mammary gland and stomach tumors11690 uah
- Amplification of HER‐2/NEU, FISH11690 uah
- IHC (НЕR2/neu)1940 uah
- IHC (ER, PR) study of the hormonal status of the endometrium2180 uah
- Oncomarker of the ovarian (CA 125)530 uah
- IHC p16, Ki-67, HSIL verification2180 uah
- IHC (p57, Ki-67) verification of cystic drift2180 uah
- IHC CD138, verification of chronic endometritis1700 uah
- IHC (CA 125) marker of ovarian neoplasm1930 uah
- Histological examination to determine BRAF V600 by PCR6770 uah
- Determination of BRAF V600 by PCR (CM material or peripheral blood)6380 uah
- Molecular genetic examination: panel for diagnostics of thyroid cancer mutations BRAF, NRAS, KRAS, NRAS, RET / PTC1, RET / PTC3, PAX8 / PPARg (punctate)7590 uah
- EGFR Mutations, PCR7590 uah
- ALK Translocation, FISH10820 uah
- ROS1 Translocation, FISH8640 uah
- Determination of DNA mismatch repair proteins (microsatellite stability/instability of the tumor)4290 uah
- Determination of t(9;22)(q34.1;q11.2) BCR-ABL1 (Philadelphia chromosome) by FISH method5960 uah
- Determination of BCR-ABL1 (p210) (Philadelphia chromosome) by PCR method10820 uah
- Determination of BCR-ABL1 (p190) (Philadelphia chromosome) by PCR method10820 uah
- Karyotyping in oncohematological diseases6770 uah
- Determination of t(12;21)(p13.2;q22.1) by FISH method5600 uah
- Determination of t(15;17)(q24;q21) by the FISH method5280 uah
- FISH definition of inv(16)(p13.1q22)/t(16;16)6310 uah
- Determination of del17p13 by FISH method5280 uah
- Determination of Del 5q by the FISH method5280 uah
- Determination of del(7q) by the FISH method5280 uah
- Determination of del(20q) by the FISH method5280 uah
- Interoperable study of the material (stage 1)2530 uah
- Interoperational study of the material (stage 2 and subsequent stages)1700 uah
- Micrographic surgery (Mohs, Slow Mohs) (for the second and subsequent stages, for each)1580 uah
- Micrographic surgery (Mohs, Slow Mohs) (for the first stage)2920 uah
- Histological examination after radical resection of the breast and mastectomy (one side) *4090 uah
- Histological examination after Lobectomy and pulmonectomy *4090 uah
- Histological examination after Lobectomy of the thyroid gland4940 uah
- Histological examination after gastrectomy, subtotal gastrectomy *5490 uah
- Histological examination after biopsy of soft tissue tumor formations1540 uah
- Histological examination after appendix removal during tumor processes2190 uah
- Histological examination after removal of the gallbladder in tumor processes2190 uah
- Histological examination after removal of odontogenic tumor, skull bone tumor2190 uah
- Histological examination after removal of bone and joint tumor, bone resection for tumor pathology3270 uah
- Histological examination after removal of tumor of the oral/ nasal cavities2190 uah
- Histological examination after the removal of uterine appendages with ovarian tumors (one side)2190 uah
- Histological examination after removing a tumor of the brain, spinal cord, membranes2280 uah
- Prostate-specific antigen (PSA) free + total (cito)1590 uah
- Prostate-specific antigen (PSA) total (cito)980 uah
- OncoRisk BRCA1/2 - Panel of hereditary mutations of BRCA1 and BRCA2 genes, NGS18260 uah
- OncoRisk BRCA Plus - Genetic panel for Breast and Ovarian Cancer (14 genes)17330 uah
- Histological examination after excisional biopsy of skin tumor with assessment of resection edges (for 1 localization)1700 uah
- Histological examination after penile formation excision biopsy2180 uah
- Histological examination after enucleation, partial prostatectomy2180 uah
- Immunocytochemical study of exudate fluids in metastatic processes5960 uah
- OncoRisk Colorectal - Genetic panel for colorectal cancer (19 genes)19260 uah
- OncoRisk Complete - Comprehensive panel for hereditary cancer (88 genes)31960 uah
- OncoRisk Lynch - Lynch syndrome diagnosis (5 genes)17210 uah
- OncoRisk Renis - Genetic panel for renal cancer (25 genes)19260 uah
- OncoRisk Prostate - Genetic panel for prostate cancer (15 genes)16370 uah
- Quantification of BCR-ABL1 p190 translocation by PCR10820 uah
- Quantitative determination of the leukemia marker BCR-ABL1 p210, PCR10820 uah
- Comprehensive cytogenetic testing (Karyotyping + FISH) oncohematology11690 uah
- Histological examination after removal of ureter/part of ureter (in case of tumor pathology)2180 uah
- Histological examination after wedge resection/ovarian biopsy (tumor pathology, on the one side)2280 uah
- Histological examination after biopsy of intestinal tumors (up to 3 localizations of biopsy included)1750 uah
- Histological examination after uterine removal without appendages (in case of tumor pathology)2420 uah
- Histological examination after removal of the appendages of the uterus (in case of tumor pathology, on one side)2280 uah
- Histological examination after ovarian removal (in case of tumor pathology, on one side)2280 uah
List of sources, literature ↓
- Аляев Ю.Г., Винаров А.З., Крапивин А.А. Диагностика опухоли лоханки и мочеточника. В кн.: Тезисы VI Всероссийской научно-практической конференции Актуальные вопросы лечения онкоурологических заболеваний 4-5 октября 2005 г. Онкоурология (приложение) 2005: прил.: 5-6.
- Книшов Г.В., Витовский Р.М., Захарова В.П. (2005) Опухоли сердца, проблемы диагностики и хирургического лечения. Киев, 256 с.
- Клинические рекомендации по диагностике и лечению больных с опухолями верхних мочевыводящих путей. Ассоциации онкологов России. Москва 2014.